The initiation and the continuing commitment
Initiation is usually the most concentrated phase of a mandate. The analyst studies the reporting history, operating segments, competitors, and relevant sector evidence. The team then builds the forecast, reconciles it to reported financials, tests the valuation, and writes and edits the report. A company with a recent acquisition or a new reporting structure may require additional work to reconstruct comparable periods before meaningful forecasting can begin.
A proposal may commission just the initiation or include it in a continuing agreement. With continuing coverage, the provider allocates analyst capacity to scheduled results and material events after publication. Ask whether the initiation is priced separately, what the recurring fee covers, and how work outside the agreed scope is handled. A fee that includes scheduled earnings updates, model revisions, and event coverage should be evaluated against the full term and deliverables.
Some distribution frameworks affect what can be contracted. If an engagement is intended to qualify for the issuer-sponsored label under MiFID II, the final EU code sets terms affecting initial duration, renewal, and the timing of payment. Review the EU guide and the adopted regulation when defining a cross-border mandate.
Model complexity and analyst time
The shape of a business often explains model effort better than its market capitalization. A single-product operator with a long reporting history may support one integrated operating forecast. A pre-revenue biotech with several indications may need separate development timelines, probabilities, patient forecasts, and cost schedules that roll into one cash runway. A mining developer with interests in multiple projects may require separate production profiles, royalties, investment schedules, and ownership adjustments. Those are materially different assignments.
Consider what is documented and what must be estimated. Segment disclosures, backlog, reserve estimates, and trial details vary in quality and frequency. Where the public evidence is incomplete, the analyst has to decide how to make an estimate, identify the limitation, and show how sensitive the result is to the assumption. Ask how the provider will handle those gaps and what level of model detail it can substantiate.
The proposed team also affects the fee. Financial modeling, writing, and review are distinct responsibilities even when one analyst handles several of them. Find out who will lead the research, whether they have covered the relevant business or development stage, and who will review the work. The published examples and the model outline are a better basis for this conversation than the promised number of pages.
Updates are a commitment of analyst capacity
Quarterly reporting can generally be scheduled in advance. A financing, regulator decision, or asset development may occur between reporting dates. A brief note that describes a release demands less work than a revision that changes the operating model, adds a funding scenario, and reassesses valuation. Determine which kinds of events are covered, how the provider prioritizes them against regular reporting, and when a separate scope change would be agreed.
Look at the term and any limits on update work together. A mandate for a company approaching several clinical milestones needs room for events that can shift in timing. A well-defined proposal states how these events are handled and how updates that materially change estimates are documented. That makes the cost comparison fairer than assuming every deliverable labeled an update is equivalent.
For a company with one dominant development asset, ask how the fee would change if you add a second asset, acquire a commercial operation, or announce a restructuring. A change clause should say how additional work is approved and whether the provider can continue with the originally agreed update schedule while the new scope is being negotiated. You can then compare the ordinary annual commitment and the cost of expanding coverage separately.
What to put side by side
Ask each provider to specify the same categories, even if it prices the work differently. This is especially helpful when distribution is described broadly. Public hosting, institutional report delivery, model access, estimate submission, and third-party syndication are separate capabilities. Ask which are part of the fee, which depend on platform acceptance, and which could involve additional charges.
Use the provider diligence guide to assess the work behind the proposal before comparing the commercial terms.
| Proposal item | What to verify |
|---|---|
| Initiation scope | Identify the business units or assets to be covered, the primary evidence the analyst will use, the publication format, and the proposed timing. |
| Financial model | Ask which schedules will be built, which scenarios will be tested, and who can access the workbook after publication. |
| Continuing coverage | Confirm the earnings schedule, material-event criteria, and whether model and valuation revisions are included. |
| Distribution | Request named outlets, eligible formats, subscription requirements, and confirmation of any third-party costs or conditions. |
| Commercial and editorial terms | Compare total commitment, payment schedule, re-scoping and renewal terms, editorial authority, and treatment of published work at the end of the mandate. |
Frequently asked questions
Can we commission an initiation and add coverage later?
Some providers structure engagements that way. Ask how the model will be maintained in the interim, whether future work can rely on it, and whether your intended distribution imposes minimum contract terms.
Does a lower fee usually mean less model detail?
The fee alone tells you little. Compare model schedules, analyst responsibility, review process, and the scope of updates. A simple business may support a compact model with well-documented assumptions, while a complex group of assets may need extensive schedules.
What information helps AER scope a proposal?
Your ticker, exchange, latest annual and interim filings, investor materials, public milestone calendar, and intended audience help us estimate the research and model work. We agree the commercial terms after defining the scope.